Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Decline in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant drop in short interest in September. As of September 15th, there was short interest totalling 467,200 shares, a drop of 70.2% from the August 31st total of 1,570,000 shares. Based on an average daily volume of 20,860,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.3% of the company’s stock are sold short.

Tonix Pharmaceuticals Stock Up 1.3 %

NASDAQ TNXP traded up $0.00 during trading hours on Wednesday, reaching $0.13. 1,219,386 shares of the company were exchanged, compared to its average volume of 7,506,082. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.72 and a current ratio of 1.15. The business’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $3.30. Tonix Pharmaceuticals has a 1 year low of $0.13 and a 1 year high of $26.56.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The business had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. On average, equities research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TNXP. StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday, September 18th. They set a “sell” rating on the stock. Alliance Global Partners raised their price objective on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.